Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1247661

Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy


Mihaljević, Vjera; Zjalić, Milorad; Kizivat, Tomislav; Omanović Kolarić, Tea; Smolić, Martina; Rođak, Edi; Čović, Marina; Kuna, Lucija; Smolić, Robert; Včev, Aleksandar; Bilić Ćurčić, Ines
Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy // Biomedicines, 10 (2022), 11; 2983, 13 doi:10.3390/biomedicines10112983 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1247661 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy

Autori
Mihaljević, Vjera ; Zjalić, Milorad ; Kizivat, Tomislav ; Omanović Kolarić, Tea ; Smolić, Martina ; Rođak, Edi ; Čović, Marina ; Kuna, Lucija ; Smolić, Robert ; Včev, Aleksandar ; Bilić Ćurčić, Ines

Izvornik
Biomedicines (2227-9059) 10 (2022), 11; 2983, 13

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
diabetic nephropathy ; TGF-β1 ; empagliflozin ; LLC-PK1 cells

Sažetak
Aims: Chronic diabetes complications, including diabetic nephropathy (DN), frequently result in end-stage renal failure. This study investigated empagliflozin (SGLT2i) effects on collagen synthesis, oxidative stress, cell survival, and protein expression in an LLC-PK1 model of DN. Methods: Combinations of high glucose (HG) and increasing empagliflozin concentrations (100 nM and 500 nM), as well as combinations of HG, H2O2, and empagliflozin, were used for cell culture treatment. The cell viability, glutathione (tGSH), ECM expression, and TGF-β1 concentration were measured. In addition, the protein expression of Akt, pAkt, GSK3, pGSK3, pSTAT3, and SMAD7 was determined. Results: The addition of both concentrations of empagliflozin to cells previously exposed to glucose and oxidative stress generally improved cell viability and increased GSH levels (p < 0.001, p < 0.05). In HG30/H2O2/Empa500-treated cells, significant increase in pSTAT3, pGSK3β, GSK3β, SMAD7, and pAKT levels (p < 0.001, p < 0.001, p < 0.05) was observed except for AKT. Lower drug concentrations did not affect the protein expression levels. Furthermore, empagliflozin treatment (100 nM and 500 nM) of HG30/H2O2-injured cells led to a decrease in TGF-β1 levels (p < 0.001). In cells exposed to oxidative stress and hyperglycemia, collagen production remained unchanged. Conclusion: Renoprotective effects of empagliflozin, in this LLC-PK1 cell model of DN, are mediated via activation of the Akt/GSK-3 signalling pathway, thus reducing oxidative stress-induced damage, as well as enhanced SMAD7 expression leading to downregulation of TGF-β1, one of the key mediators of inflammation and fibrosis.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti, Farmacija



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek,
Fakultet za dentalnu medicinu i zdravstvo, Osijek

Poveznice na cjeloviti tekst rada:

doi www.mdpi.com

Citiraj ovu publikaciju:

Mihaljević, Vjera; Zjalić, Milorad; Kizivat, Tomislav; Omanović Kolarić, Tea; Smolić, Martina; Rođak, Edi; Čović, Marina; Kuna, Lucija; Smolić, Robert; Včev, Aleksandar; Bilić Ćurčić, Ines
Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy // Biomedicines, 10 (2022), 11; 2983, 13 doi:10.3390/biomedicines10112983 (međunarodna recenzija, članak, znanstveni)
Mihaljević, V., Zjalić, M., Kizivat, T., Omanović Kolarić, T., Smolić, M., Rođak, E., Čović, M., Kuna, L., Smolić, R., Včev, A. & Bilić Ćurčić, I. (2022) Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. Biomedicines, 10 (11), 2983, 13 doi:10.3390/biomedicines10112983.
@article{article, author = {Mihaljevi\'{c}, Vjera and Zjali\'{c}, Milorad and Kizivat, Tomislav and Omanovi\'{c} Kolari\'{c}, Tea and Smoli\'{c}, Martina and Ro\djak, Edi and \v{C}ovi\'{c}, Marina and Kuna, Lucija and Smoli\'{c}, Robert and V\v{c}ev, Aleksandar and Bili\'{c} \'{C}ur\v{c}i\'{c}, Ines}, year = {2022}, pages = {13}, DOI = {10.3390/biomedicines10112983}, chapter = {2983}, keywords = {diabetic nephropathy, TGF-β1, empagliflozin, LLC-PK1 cells}, journal = {Biomedicines}, doi = {10.3390/biomedicines10112983}, volume = {10}, number = {11}, issn = {2227-9059}, title = {Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy}, keyword = {diabetic nephropathy, TGF-β1, empagliflozin, LLC-PK1 cells}, chapternumber = {2983} }
@article{article, author = {Mihaljevi\'{c}, Vjera and Zjali\'{c}, Milorad and Kizivat, Tomislav and Omanovi\'{c} Kolari\'{c}, Tea and Smoli\'{c}, Martina and Ro\djak, Edi and \v{C}ovi\'{c}, Marina and Kuna, Lucija and Smoli\'{c}, Robert and V\v{c}ev, Aleksandar and Bili\'{c} \'{C}ur\v{c}i\'{c}, Ines}, year = {2022}, pages = {13}, DOI = {10.3390/biomedicines10112983}, chapter = {2983}, keywords = {diabetic nephropathy, TGF-β1, empagliflozin, LLC-PK1 cells}, journal = {Biomedicines}, doi = {10.3390/biomedicines10112983}, volume = {10}, number = {11}, issn = {2227-9059}, title = {Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy}, keyword = {diabetic nephropathy, TGF-β1, empagliflozin, LLC-PK1 cells}, chapternumber = {2983} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font